English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/143535
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract

AuthorsTorres-Cornejo, Almudena; BenMarzouk-Hidalgo, O. J.; Viciana, Pompeyo; Sánchez, Berta; López-Ruz, M .A.; López-Cortés, Luis F. ; Gutiérrez Valencia, Alicia
KeywordsProtease inhibitor monotherapy
Triple therapy
Male genital tract
Human immunodeficiency virus 1 treatment
Human immunodeficiency virus 1 infection
Issue DateJan-2016
CitationClinical Microbiology and Infection 22(1): 98.e7-98.e10 (2016)
AbstractCross-sectional study comparing seminal human immunodeficiency virus type 1 (HIV-1) shedding in patients receiving boosted protease inhibitor monotherapy (mtPI/rtv) (n = 66) versus triple therapy (TT) (n = 61). Seminal HIV-1 shedding rates in patients with undetectable plasma HIV-RNA were 16.0% on mtPI/rtv compared with 28.6% on TT (p 0.173). Aviraemic status and time on viral suppression were independently associated with lack of seminal HIV-1 shedding. During TT, non PI/rtv-based regimens were associated with a better control of HIV infection in semen despite similar time on viral suppression. The use of mtPI/rtv in well-controlled patients is not associated with increased seminal HIV excretion compared with TT.
Publisher version (URL)http://doi.org/10.1016/j.cmi.2015.09.028
Identifierse-issn: 1469-0691
issn: 1198-743X
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.